RT Journal Article
SR Electronic
T1 Validation of CXCL10 as a biomarker of respiratory tract infections detectable by lateral flow immunoassay
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 66
DO 10.1183/23120541.LSC-2022.66
VO 8
IS suppl 8
A1 Mikkelsen, Dayna
A1 Aguiar, Jennifer A.
A1 Danieli, Julia
A1 Chhabra, Prakriti
A1 Tremblay, Benjamin J-M
A1 Hunjan, Manjot S.
A1 Kirkness, Victoria
A1 Gilchrist, Jodi
A1 Bulir, David
A1 Smieja, Marek
A1 Lee, Sojin
A1 Shaikh, Nader
A1 Mbareche, Hamza
A1 Mubareka, Samira
A1 Tram, Kha
A1 Doxey, Andrew C.
A1 Hirota, Jeremy
YR 2022
UL http://openres.ersjournals.com/content/8/suppl_8/66.abstract
AB Introduction: Biomarkers of respiratory tract infections historically focused on the etiological cause of infection, although much of the morbidity and mortality is driven by the host-pathological response.Aim: Determine host biomarkers indicative of viral respiratory tract infections that are amenable to lateral flow immunoassay (LFIA) testing.Methods: Datamining was performed on in-house and publicly available datasets from respiratory syncytial virus (RSV), rhinovirus, influenza A and SARS-CoV-2 infected patient nasopharyngeal swab samples and compared to healthy controls. CXCL10, CXCL11 and TNFSF10 gene expression levels were assessed and a correlation analysis was performed in relation to infection severity and time-course. Lastly, the signature was validated at the protein level in saliva as a prerequisite for development of a host-response LFIA.Results: CXCL10 and CXCL11 upregulation was positively correlated with RSV when compared to control (p= 0.016, p= 0.006). No significant association was found with influenza A or rhinovirus for all three genes. CXCL10/CXCL11/TNFSF10 upregulation was positively correlated with SARS-CoV-2 infection when compared to control (p < 0.001). CXCL10 expression correlated with COVID-19 severity and had the lowest variance over infection time-course. CXCL10 was not detected at the protein level in healthy saliva but was elevated in saliva from COVID-19 patients. A CXCL10 LFIA was developed with a sensitivity of 2 ng/ml in a buffer and artificial saliva.Conclusion: The findings validate the potential utility of examining host immune responses during viral respiratory tract infections by exploring CXCL10 as a biomarker detectable by LFIA.FootnotesCite this article as ERJ Open Research 2022; 8: Suppl. 8, 66.This article was presented at the 2022 ERS Lung Science Conference, in session “Poster Session 2”.This is an ERS Lung Science Conference abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).